 The survival of esophageal cancer and stomach cancer EGC at 5 years is less than 30. Pravastatin is a potent inhibitor of HMG-CoA reductase inhibitor that has shown increased survival in patients with advanced hepatocellular carcinoma. The objective is to evaluate the efficacy of treatment increase in survival and recurrence-free period of the disease with pravastatin in patients with advanced EGC. The investigators have designed a randomized, controlled and open. Advanced stage was considered for patients with T4 or N1 or M1 according to the TNM classification. It has been estimated sample size per treatment arm of 73 patients 146 patients in total. Randomization was done on a stratified by location CE or CG. All patients receive hatitual treatment surgery and or chemotherapy and or radiotherapy and or palliative for each of their clinical conditions. The experimental group will receive one tablet of 40 mg of pravastatin orally every 24 hours breakfast for 2 years. There will be a monthly monitoring of these patients for at least 2 years which includes an analytics. Every 2 months there will be an abdominal-pelvic CT scan to assess progression and treatment response. 